# OnCo record cd20-expression (biomarker). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/biomarkers/cd20-expression/>
  a schema:MedicalTest ;
  onco:kind "biomarker" ;
  schema:identifier "cd20-expression" ;
  schema:name "CD20 expression (CD20-positive)"@en ;
  schema:alternateName "CD20-positive"@en, "CD20+"@en, "CD20 expression"@en, "CD20 positive lymphoma"@en, "CD20 loss"@en ;
  schema:description "CD20 is the B-cell antigen rituximab made famous. Rituximab and obinutuzumab labels are written for CD20-positive lymphoma and leukaemia; the newer CD20 x CD3 bispecifics assume it."@en ;
  schema:url <https://onco.cc/biomarkers/cd20-expression/> ;
  schema:dateModified "2026-09-23"^^xsd:date ;
  schema:citation <https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b172773b-3905-4a1c-ad95-bab4b6126563> ;
  onco:tag "biomarker", "surface-antigen" ;
  onco:related <https://onco.cc/biomarkers/cd19-expression/>, <https://onco.cc/biomarkers/cd22-expression/> ;
  onco:cancers <https://onco.cc/cancers/non-hodgkin-lymphoma/>, <https://onco.cc/cancers/dlbcl/>, <https://onco.cc/cancers/follicular-lymphoma/>, <https://onco.cc/cancers/cll/>, <https://onco.cc/cancers/mantle-cell-lymphoma/>, <https://onco.cc/cancers/marginal-zone-lymphoma/> ;
  onco:drugs <https://onco.cc/drugs/rituximab/>, <https://onco.cc/drugs/obinutuzumab/>, <https://onco.cc/drugs/mosunetuzumab/>, <https://onco.cc/drugs/glofitamab/>, <https://onco.cc/drugs/epcoritamab/> ;
  onco:terms <https://onco.cc/terms/ihc/>, <https://onco.cc/terms/flow-cytometry/>, <https://onco.cc/terms/antigen-escape/> .